IXINITY delivers low clearance1

LOW CLEARANCE

FOR HEMOPHILIA B PATIENTS1

down icon
up icon

HIGH FACTOR IX LEVELS

FOR PATIENTS OVER TIME2

Man throwing a frisbee
caret left icon

Watch the LOW CLEARANCE. HIGH COVERAGE. video

See the data behind the low clearance and high coverage of IXINITY.
CTA icon

Connect with your local IXINITY Specialist and see if IXINITY is the right treatment for your patients.

*Phase 3 controlled, multicenter study of 76 patients designed to evaluate PK noninferiority of IXINITY to a comparator standard half-life rFIX, and to establish safety and hemostatic efficacy of IXINITY in previously treated adolescents and adults (≥12 years of age) with severe (FIX activity <1 IU/dL) and moderately severe (FIX activity ≤2 IU/dL) hemophilia B.1

FIX = factor IX; PK = pharmacokinetic; r = recombinant.

References: 1. IXINITY [coagulation factor IX (recombinant)]. Prescribing information. Chicago, IL: Medexus Pharma, Inc.; November 2022. 2. Data on file. Chicago, IL, Medexus Pharma, Inc. 3. Collins PW, Quon DVK, Makris M, et al. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia. 2018;24:104-112.

The information in this section is intended for healthcare providers in the United States. I certify that I am a healthcare provider in the United States.

Yes
No